DelMar Pharmaceuticals (DMPI) PT Set at $12.00 by HC Wainwright
DelMar Pharmaceuticals (NASDAQ:DMPI) received a $12.00 price target from analysts at HC Wainwright in a research note issued to investors on Thursday. The firm presently has a “buy” rating on the stock.
Separately, Maxim Group reaffirmed a “hold” rating on shares of DelMar Pharmaceuticals in a report on Monday, September 11th.
DelMar Pharmaceuticals (NASDAQ:DMPI) opened at $1.68 on Thursday. DelMar Pharmaceuticals has a fifty-two week low of $0.78 and a fifty-two week high of $5.39. The firm has a market cap of $36.29, a price-to-earnings ratio of -2.46 and a beta of 1,227.20.
DelMar Pharmaceuticals (NASDAQ:DMPI) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). analysts predict that DelMar Pharmaceuticals will post -0.54 earnings per share for the current fiscal year.
In other news, CEO Saiid Zarrabian acquired 60,900 shares of the business’s stock in a transaction on Tuesday, November 14th. The stock was bought at an average price of $0.82 per share, with a total value of $49,938.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in DMPI. Franklin Resources Inc. purchased a new position in DelMar Pharmaceuticals in the second quarter valued at $2,477,000. Sabby Management LLC acquired a new stake in shares of DelMar Pharmaceuticals in the second quarter valued at about $1,484,000. Finally, Susquehanna International Group LLP acquired a new stake in shares of DelMar Pharmaceuticals in the third quarter valued at about $306,000. 16.91% of the stock is owned by institutional investors.
About DelMar Pharmaceuticals
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.